A Phase II, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
A Phase II, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
This is a randomized, double blind, placebo-controlled, phase II study. The study will be performed as a multicenter, multinational study.
Inclusion Criteria:
Exclusion Criteria:
Segmental vitiligo, focal, or mixed Vitiligo
Subjects who have high risk of suicidality at the Screening assessment based on Investigator's judgment
History of alcohol or drug abuse in the previous 2 years
Subjects who were submitted to melanocyte transfer
-